非M3型急性白血病患者中MUC1基因和MDR1基因表达及其与临床疗效的关系  

Expression of MUC1 Gene and MDR1 Gene in Non-M3 Subtype Acute Leukemia and Their Correlations to Clinical Treatment Efficacy

作　　者：黎国伟[1,2] 王东宁[1] 林东军[1] 李旭东[1] 林桂真[1] 何易[1] 林曲[1] 黄仁魏[1] 

机构地区：[1]中山大学附属第三医院血液科 [2]惠州市中心人民医院血液科,广东惠州516001

出　　处：《癌症》2005年第8期1011-1014,共4页Chinese Journal of Cancer

基　　金：广东省医学科学研究基金(No.B2003153)~~

摘　　要：背景与目的:MUC1基因在胃癌、卵巢癌、多发性骨髓瘤、恶性淋巴瘤等肿瘤中有表达,在急性白血病患者中有较高的表达。但MUC1基因和多药耐药基因(MDR1)相互关系以及两者的表达与急性白血病治疗效果的关系尚有待探讨。本研究拟探讨MUC1基因与MDR1基因表达及其与非M3型急性白血病患者治疗效果的关系。方法:应用逆转录鄄聚合酶链反应(RT鄄PCR)法检测34例初治非M3型急性白血病患者MUC1和MDR1的表达,并观察两种基因表达及其与临床疗效的关系。结果:34例初治非M3型急性白血病患者中MUC1基因阳性率为50%,MDR1基因阳性率为29.4%。MUC1基因阳性患者的MDR1阳性率为52.9%,明显高于MUC1阴性者的5.9%(P=0.003)。MUC1基因阴性者完全缓解(CR)率达94.1%,阳性患者CR率52.9%,两组有显著性差异(P<0.05);MDR1基因阴性者CR率为91.7%,明显高于阳性患者的50.0%(P<0.05)。MUC1基因和MDR1基因均阳性者CR率为55.6%,MUC1基因和MDR1基因均阴性者16例,全部获得CR。结论:非M3型急性白血病MUC1基因阳性者MDR1基因表达率较高,MUC1基因及MDR1基因均为阴性者治疗缓解率高。提示联合检测MUC1基因和MDR1基因对判断初治非M3型急性白血病的疗效有良好的预测作用,可作为临床判断疗效的一项有意义的指标。BACKGROUND ＆ OBJECTIVE. Mucin 1 （MUC1） gene is expressed in various tumors, and overexpressed in acute leukemia. This study was to evaluate the expression of MUC1 gene and multidrug-resistance protein-1 （MDR1） gene in non-M3 subtype acute leukemia and their correlations to clinical treatment efficacy. METHODS： The expression of MUC1 and MDR1 genes were measured in 34 patients with non-M3 subtype acute leukemia by reverse transcription-polymerase chain reaction （RT-PCR）;their correlations to clinical treatment efficacy were observed. RESULTS： The positive rate of MUC1 gene in the 34 patients was 50.0%, and the positive rate of MDR1 gene was 29.4%. The positive rate of MDR1 was significantly higher in MUC1-positive patients than in MUCl-negative patients （52.9% vs.5.9%, P=0,003）. Complete remission （CR） rate was significantly higher in MUC1-negative patients than in MUC1-positive patients （94.1% vs. 52.9%,P〈0.01）. CR rate was significantly higher in MDR1-negative patients than in MDR1-positive patients （91.7% vs. 50.0%, P〈0.05）. In 9 patients with positive expression of both MUC1 and MDR1, the CR rate was 55.6%; whilein 16 patients with negative expression of both MUC1 and MDR1, the CR rate was 100%. CONCLUSIONS： The non-M3 subtype acute leukemia patients with positive expression of MUC1 have high positive rate of MDR1. The patients with negative expression of both MUC1 and MDR1 have high CR.Co-detection of MUC1 gene and MDR1 gene can predict treatment efficacy on non-M3 subtype acute leukemia.

关 键 词：白血病/药物疗法 MUC1基因 多药耐药基因 疗效 预测指标 

分 类 号：R733.7[医药卫生—肿瘤]